This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Takeda Pharmaceutical Company Ltd
Drug Names(s): Tandemact (EU), glimepiride and pioglitazone (Actos), Sonias (Japan)
Description: Duetact is a combination of two diabetic drugs.
Pioglitazone (Actos) is a thiazolidinedione that decreases insulin resistance in the periphery and in the liver, resulting in increased insulin-dependent glucose disposal and decreased hepatic glucose output. Pioglitazone is a potent and highly selective agonist for peroxisome proliferator-activated receptor-gamma (PPARg). Activation of PPARg nuclear receptors modulates the transcription of a number of insulin responsive genes involved in the control of glucose and lipid metabolism.
Glimepiride is a sulfonylurea. Its primary mechanism of action appears to be dependent on stimulating the release of insulin from functioning pancreatic beta cells. In addition, extrapancreatic effects may also play a role in the activity of sulfonylureas such as glimepiride.
Pink Sheet November Supplemental Approvals
Additional information available to subscribers only: